Packages (Simulation)
Reagent Preparation
Image (I)
Image (II)
Certificate
Multiplex Assay Kit for Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay)
G3PD; GAPD; Peptidyl-cysteine S-nitrosylase GAPDH
(Note: Up to 8-plex in one testing reaction)
- Product No.LMB932Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Sample TypeTissue homogenates, cell lysates, cell culture supernates and other biological fluids
- Test MethodDouble-antibody Sandwich
- Assay Length3.5h
- Detection Range0.1-100ng/mL
- SensitivityThe minimum detectable dose of this kit is typically less than 0.033 ng/mL.
- DownloadInstruction Manual
- UOM 8Plex 7Plex 6Plex 5Plex 4Plex 3Plex 2Plex1Plex
- FOB
US$ 415
US$ 431
US$ 455
US$ 487
US$ 519
US$ 567
US$ 638
Result
For more details, please contact local distributors! US$ 798 Add to Price Calculator
Specificity
This assay has high sensitivity and excellent specificity for detection of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.
Recovery
Matrices listed below were spiked with certain level of recombinant Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.
Matrix | Recovery range (%) | Average(%) |
serum(n=5) | 82-103 | 85 |
EDTA plasma(n=5) | 89-96 | 92 |
heparin plasma(n=5) | 92-105 | 96 |
sodium citrate plasma(n=5) | 90-97 | 94 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Glyceraldehyde-3-Phosphate Dehydrogenase (GAPDH) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
Sample | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 79-94% | 96-104% | 82-93% | 96-103% |
EDTA plasma(n=5) | 92-101% | 80-89% | 94-102% | 80-101% |
heparin plasma(n=5) | 80-101% | 96-104% | 88-101% | 92-101% |
sodium citrate plasma(n=5) | 81-96% | 89-103% | 79-104% | 88-95% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
Reagents | Quantity | Reagents | Quantity |
96-well plate | 1 | Plate sealer for 96 wells | 4 |
Pre-Mixed Standard | 2 | Standard Diluent | 1×20mL |
Pre-Mixed Magnetic beads (22#:GAPDH) | 1 | Analysis buffer | 1×20mL |
Pre-Mixed Detection Reagent A | 1×120μL | Assay Diluent A | 1×12mL |
Detection Reagent B (PE-SA) | 1×120μL | Assay Diluent B | 1×12mL |
Sheath Fluid | 1×10mL | Wash Buffer (30 × concentrate) | 1×20mL |
Instruction manual | 1 |
Assay procedure summary
1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.
GIVEAWAYS
INCREMENT SERVICES
Magazine | Citations |
Clin Cancer Res | Inactivation of the p53–KLF4–CEBPA Axis in Acute Myeloid Leukemia PubMed: 26408402 |
Clin Cancer Res | Inactivation of the p53–KLF10–CEBPA Axis in Acute Myeloid Leukemia PubMed: 26408402 |
Diabetes & Metabolism | Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. pubmed:28499695 |
Scientific Reports | Adhesion of Toxoplasma gondii tachyzoite-infected vehicle leukocytes to capillary endothelial cells triggers timely parasite egression pubmed:28720868 |
Journal of Biological Chemistry | Biochemical characterization of the PHARC associated serine hydrolase ABHD12 reveals its preference for very long chain lipids Pubmed: 30237167 |
Biomaterials | Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels Pubmed: 30343256 |
Bulletin of Experimental Biology and Medicine | Influence of Magnetite Nanoparticles and Quantum Dots on the Expression of Reference Genes in Peripheral Blood Cells Pubmed: 30488202 |
Journal of Medicinal Chemistry | Discovery, Optimization and Target Identification of Novel Potent Broad-Spectrum Antiviral Inhibitors Pubmed: 30938999 |
International Immunopharmacology | Methionine enkephalin (MENK) regulates the immune pathogenesis of type 2 diabetes mellitus via the IL-33/ST2 pathway Pubmed: 31078923 |
Cancers | Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075 |
Biological research | Linc-OIP5 in the breast cancer cells regulates angiogenesis of human umbilical vein endothelial cells through YAP1/Notch/NRP1 signaling circuit at a tumor … Pubmed: 32046779 |
Biomed Pharmacother | Silence of FAM83H-AS1 promotes chemosensitivity of gastric cancer through Wnt/β-catenin signaling pathway Pubmed: 32028241 |
Metab Brain Dis | Ginger and turmeric lipid-solubles attenuate heated oil-induced oxidative stress in the brain via the upregulation of NRF2 and improve cognitive function in rats Pubmed: 33170419 |
South African Journal of Botany | Evaluation of the effect of herbal extracts and their bioactive compounds against motion sickness by regulating neurotransmitter levels in vitro and in vivo |
Regulation of hepatic lipid metabolism in CB1-/-and Abcb4-/--HBV surface protein transgenic mice | |
Cancers (Basel) | BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760 |
MOLECULAR CANCER RESEARCH | Omega-3 Eicosapentaenoic Acid Reduces Prostate Tumor Vascularity 33262291 |
Sci Rep | Curcumin derivative ST09 modulates the miR-199a-5p/DDR1 axis and regulates proliferation and migration in ovarian cancer cells 34837026 |
Cancer Rep (Hoboken) | Curcumin alters distinct molecular pathways in breast cancer subtypes revealed by integrated miRNA/mRNA expression analysis Pubmed:34981672 |
Prog Neurobiol | Retinoic acid receptor beta protects striatopallidal medium spiny neurons from mitochondrial dysfunction and neurodegeneration Pubmed:35151792 |
Plant Molecular Biology | Arabidopsis GELP7 functions as a plasma membrane-localized acetyl xylan esterase, and its overexpression improves saccharification efficiency Pubmed:35577991 |